- €164.69m
- €175.17m
- €17.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -529.35% | ||
| Return on Equity | -1642.76% | ||
| Operating Margin | -587.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 7 | 0.37 | 4.19 | 12.18 | 17.48 | 2.88 | 13.25 | 40.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Directors
- Frederic Cren CHM
- Pierre Broqua DCE
- Jean Volatier CFO
- Nathalie Harroy CHO
- David Nikodem VOP
- Susan Coles EXB
- Michael Cooreman EXB
- Chris Buyse IND (55)
- Lucy Lu IND (45)
- Heinz Maeusli IND (58)
- Annick Schwebig IND (69)
- Martine Zimmerman IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 25th, 2011
- Public Since
- February 15th, 2017
- No. of Employees
- 112
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Euronext - Paris- Shares in Issue
- 52,115,807
- Address
- 50 rue de Dijon, Daix, DAIX, 21121
- Web
- https://inventivapharma.com/
- Phone
- +33 380447500
- Auditors
- Lison Chouraki Audit
Latest News for IVA
Upcoming Events for IVA
Q1 2024 Inventiva SA Corporate Sales Release
Half Year 2024 Inventiva SA Earnings Release
Similar to IVA
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
As of Today at 19:11 UTC, shares in Inventiva SA are trading at €3.16. This share price information is delayed by 15 minutes.
Shares in Inventiva SA last closed at €3.16 and the price had moved by +31.67% over the past 365 days. In terms of relative price strength the Inventiva SA share price has outperformed the FTSE Global All Cap Index by +20.98% over the past year.
The overall consensus recommendation for Inventiva SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Inventiva SA does not currently pay a dividend.
Inventiva SA does not currently pay a dividend.
Inventiva SA does not currently pay a dividend.
To buy shares in Inventiva SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €3.16, shares in Inventiva SA had a market capitalisation of €164.69m.
Here are the trading details for Inventiva SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: IVA
Based on an overall assessment of its quality, value and momentum Inventiva SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Inventiva SA is €12.20. That is 286.08% above the last closing price of €3.16.
Analysts covering Inventiva SA currently have a consensus Earnings Per Share (EPS) forecast of -€2.02 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inventiva SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -22.35%.
As of the last closing price of €3.16, shares in Inventiva SA were trading -11.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Inventiva SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €3.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Inventiva SA's management team is headed by:
- Frederic Cren - CHM
- Pierre Broqua - DCE
- Jean Volatier - CFO
- Nathalie Harroy - CHO
- David Nikodem - VOP
- Susan Coles - EXB
- Michael Cooreman - EXB
- Chris Buyse - IND
- Lucy Lu - IND
- Heinz Maeusli - IND
- Annick Schwebig - IND
- Martine Zimmerman - IND